Wednesday, May 9, 2012

From U Michigan: Vitamin D receptor in lung adenocarcinoma

http://www.ncbi.nlm.nih.gov/pubmed/22564539


Lung Cancer. 2012 May 5. [Epub ahead of print]

Characterization of vitamin D receptor (VDR) in lung adenocarcinoma.

Source

Division of Medical Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, United States; College of Pharmacy, Ajou University, Suwon, Republic of Korea.

Abstract

PURPOSE:

The anti-proliferative effects of 1α,25-dihydroxyvitamin D(3) (1,25-D(3), calcitriol, the active form of vitamin D) are mediated by the nuclear vitamin D receptor (VDR). In the present study, we characterized VDR expression in lungadenocarcinoma (AC).

EXPERIMENTAL DESIGN:

We examined VDR mRNA expression using a quantitative real-time PCR (qRT-PCR) in 100 patients who underwent surgery for lung AC. In a subset of these patients (n=89), we examined VDR protein expression using immunohistochemistry. We also examined the association of VDR protein expression with circulating serum levels of 25-hydroxyvitamin D(3) (25-D(3)) and 1,25-D(3). The antiproliferative effects and cell cycle arrest of 1,25-D(3) were examined using lung cancer cell lines with high (SKLU-1) as well as low (A549) expression of VDR mRNA.

RESULTS:

Higher VDR expression correlates with longer survival after adjusting for age, sex, disease stage and tumor grade (HR 0.73, 95% CI 0.58-0.91). In addition, there was a positive correlation (r=0.38) between serum 1,25-D(3) and tumor VDR protein expression. A greater anti-proliferative effect of 1,25-D(3) was observed in high compared to low VDR-expressing cell lines; these effects corresponded to G1 cell cycle arrest; this was associated with a decline in cyclin D1, S-phase kinase protein 2 (Skp2), retinoblastoma (Rb) and minichromosome maintenance 2 (MCM2) proteins involved in S-phase entry.

CONCLUSIONS:

Increased VDR expression in lung AC is associated with improved survival. This may relate to a lower proliferative status and G1 arrest in high VDR-expressing tumors.

No comments:

Post a Comment